Page 7 - ப்ரோக்ர்யாம் நிர்வாகி அலுவலகம் க்கு இரசாயன News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 27.4% as of 10:17 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800. So what The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today s major sell-off of the biotech stock after this news isn t surprising. 

United statesUs department of defenseProgram executive office for chemicalInovio pharmaceuticalsNuclear defenseDefense departmentJoint program executive officeOperation warp speedEmergency use authorizationsஒன்றுபட்டது மாநிலங்களில்எங்களுக்கு துறை ஆஃப் பாதுகாப்புப்ரோக்ர்யாம் நிர்வாகி அலுவலகம் க்கு இரசாயனஅணு பாதுகாப்புபாதுகாப்பு துறைகூட்டு ப்ரோக்ர்யாம் நிர்வாகி அலுவலகம்செயல்பாடு போரிடு வேகம்